BRIEF-EMA'S PRAC extends safety review of chronic Hep C treatments
April 15, 2016 at 08:26 AM EDT
* Started review of diabetes medicine canagliflozin after increase in amputations in ongoing trial
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.